Tpa Research Paper

Tissue plasminogen activator (tPA) is a naturally occurring serine protease found on the endothelial cells of the body which is responsible for the breaking down of blood clots in the body by acting as a catalyst in the conversion of plasminogen into plasmin (Tissue Plasminigen Activator (tPA), n.d.). The genetically modified drugs manufactured using recombinant biotechnology, which act as tPAs are known as rt-PAs (Recombinant Tissue Plasminogen Activator).The three main types of rt-PA includes alteplase, reteplase and tenecteplase. (Klabunde, 2007). Alteplase is an efficient drug which acts by breaking down the unwanted blood clots hence, it is used to treat patients with cardiovascular diseases, strokes and even blood clots in the lings. Reteplase is approved by the US food and drug administration for acute myocardial infection as it has more convenient administration and faster thrombolysis compared to alteplase. Tenecteplase and reteplase have similar functions and slightly differ from each other in regards to the method of delivery and effectiveness (Alteplase, tentecteplase and rectaplase, n.d.) Additional types of
A study of five pooled randomized controlled trials testing IV recombinant tissue plasminogen activator (rtPA) indicated that rtPA benefits women more than men; the usual gender difference, apparent among controls, was totally invalidated in the rtPA group. This invalidation of the usual gender effect among rtPA-treated patients was not confirmed. The following analyses was carried out on the baseline characteristics and functional outcomes in men vs women in the Canadian Alteplase for Stroke Effectiveness Study (CASES), a multicenter study that collected outcomes data for patients treated with rtPA in Canada to assess the safety and effectiveness of alteplase for stroke in the context of routine